Abstract
The replacement of either Tyr-181 or Tyr-188 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) by the corresponding HIV-2 RT amino acids Ile-181 or Leu-188 is known to result in active mutant enzymes (Y181I; Y188L) with virtual loss of sensitivity towards three structural classes of nonnucleoside RT inhibitors; L-697,661, nevirapine, and TIBO R82913. The bisheteroarylpiperazine (BHAP) U-90152S, a highly specific inhibitor (IC50, 0.29 +/- 0.01 microM) of HIV-1 RT, inhibited the recombinant Y181I and Y188L HIV-1 RT mutants with IC50 values of 3.6 +/- 0.15 microM and 0.71 +/- 0.02 microM, respectively. Construction and in vitro analysis of double mutants Y181I/Y188L and Y181C/Y188L of HIV-1 RT showed > 150-fold resistance to U-90152S. An HIV-2 RT mutant containing amino acids 176-190 from HIV-1 RT acquired full sensitivity to U-90152S (IC50, 0.26 +/- 0.01 microM). It is concluded that simultaneous mutations at Tyr-181 and Tyr-188 of HIV-1 RT promotes resistance to U-90152S.
References
Feb 1, 1992·AIDS Research and Human Retroviruses·P M GrobV J Merluzzi
Jun 1, 1992·Virology·K de VreeseJ Anné
May 15, 1992·Journal of Medicinal Chemistry·J M KlunderG C Chow
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·K J Connolly, S M Hammer
Jun 26, 1992·Science·L A KohlstaedtT A Steitz
Feb 1, 1990·Nature·R PauwelsJ Heykants
Dec 7, 1990·Science·V J MerluzziJ Adams
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M E GoldmanJ M Hoffman
Sep 1, 1991·Journal of Virology·J H NunbergM E Goldman
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D L RomeroL Resnick
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C K ShihJ A Griffin
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D RichmanJ Griffin
Aug 15, 1970·Nature·U K Laemmli
Jan 20, 1994·Biochemical Pharmacology·E De Clercq
Mar 1, 1994·Journal of Virology·D D RichmanD Pauletti
Jan 1, 1994·AIDS Research and Human Retroviruses·A M VandammeJ Anne
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·J BalzariniE De Clercq
Feb 13, 1995·FEBS Letters·N FanS K Sharma
Apr 1, 1993·Journal of Virology·P L BoyerS H Hughes
May 14, 1993·Journal of Medicinal Chemistry·D L RomeroW G Tarpley
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T J DuewekeW G Tarpley
Jan 1, 1993·Virology·J BalzariniE De Clercq
May 1, 1993·Antimicrobial Agents and Chemotherapy·T J DuewekeL Resnick
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·A Jacobo-MolinaP Clark
Oct 7, 1993·The New England Journal of Medicine·M S SaagJ C Kappes
Aug 1, 1993·Antimicrobial Agents and Chemotherapy·V W ByrnesB S Wolanski
Citations
Aug 16, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Lee T. Bacheler
Jan 9, 1999·The Journal of Biological Chemistry·E G ArgyrisY Paterson
Jan 6, 1999·Antiviral Chemistry & Chemotherapy·X ShaoJ S Gronowitz
Oct 7, 2004·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Erik J UhlmannMax Q Arens